Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Third Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2017 .
View HTML
Toggle Summary Intersect ENT Announces a Pivotal Study Publication of PROPEL® Contour Steroid Releasing Sinus Implant
Study Builds on the Extensive Clinical Evidence for Steroid Releasing Sinus Implants MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ: XENT) today announced a pivotal study publication of the second cohort of the prospective, randomized, blinded, multi-center
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 16, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its third quarter on November 2, 2017 .
View HTML
Toggle Summary Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant
MENLO PARK, Calif. & BARCELONA, Spain --(BUSINESS WIRE)--Oct. 8, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced the first presentation of results from RESOLVE II, a randomized,
View HTML
Toggle Summary Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant
MENLO PARK, Calif. & CHICAGO --(BUSINESS WIRE)--Sep. 9, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced presentation of a meta-analysis from two randomized studies evaluating the safety
View HTML
Toggle Summary Today's Research Report Coverage on Medical Equipment Stocks -- Lantheus, Intersect ENT, CHF Solutions, and ReWalk Robotics
NEW YORK , August 25, 2017 /PRNewswire/ -- If you want a Stock Review on LNTH, XENT, CHFS, or RWLK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today's attention is focused onto the Medical Appliances and Equipment industry, which is
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2017-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2017 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2017 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2017 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2017.
View HTML